Targeting the Hippo Pathway for Breast Cancer Therapy

Breast cancer (BC) is one of the most prominent diseases in the world, and the treatments for BC have many limitations, such as resistance and a lack of reliable biomarkers. Currently the Hippo pathway is emerging as a tumor suppressor pathway with its four core components that regulate downstream transcriptional targets. In this review, we introduce the present targeted therapies of BC, and then discuss the roles of the Hippo pathway in BC. Finally, we summarize the evidence of the small molecule inhibitors that target the Hippo pathway, and then discuss the possibilities and future direction of the Hippo-targeted drugs for BC therapy.

[1]  K. Guan,et al.  Regulation of the Hippo Pathway by Phosphatidic Acid-Mediated Lipid-Protein Interaction. , 2018, Molecular cell.

[2]  S. Bicciato,et al.  Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4 , 2018, Nature Medicine.

[3]  A. Rosenwald,et al.  TRPS1 shapes YAP/TEAD-dependent transcription in breast cancer cells , 2018, Nature Communications.

[4]  T. Ahern,et al.  Statins: a role in breast cancer therapy? , 2018, Journal of internal medicine.

[5]  Xiaolong Yang,et al.  The Hippo Pathway: Immunity and Cancer , 2018, Cancers.

[6]  H. Shen,et al.  A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis , 2018, Nature Communications.

[7]  Christian N. Cunningham,et al.  Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors , 2018, Cancers.

[8]  Dana M. Brantley-Sieders,et al.  The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ , 2017, Science Signaling.

[9]  T. Borin,et al.  Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines. , 2017, Anti-cancer agents in medicinal chemistry.

[10]  W. Barry,et al.  An open label, phase II trial of continuous low-irradiance photodynamic therapy (CLIPT) using verteporfin for the treatment of cutaneous breast cancer metastases. , 2017 .

[11]  M. Duffy,et al.  Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). , 2017, European journal of cancer.

[12]  Min Hwan Kim,et al.  Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies , 2016, Cellular and Molecular Life Sciences.

[13]  D. Berry,et al.  Abstract P6-11-04: The evaluation of ganitumab/metformin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial , 2017 .

[14]  Michael B. Stadler,et al.  The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα , 2017, Nature.

[15]  Matthew V. Holt,et al.  The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity , 2016, Cell.

[16]  Lisheng Wang,et al.  Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression , 2016, Journal of biomedical research.

[17]  E. Winer,et al.  Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. , 2016, The New England journal of medicine.

[18]  K. Irvine,et al.  Cellular Organization and Cytoskeletal Regulation of the Hippo Signaling Network. , 2016, Trends in cell biology.

[19]  Tuan S. Nguyen,et al.  Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. , 2016, Cancer discovery.

[20]  A. Fields,et al.  PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis , 2016, Oncogene.

[21]  Davide Esposito,et al.  Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations , 2016, Oncotarget.

[22]  B. N. Devaiah,et al.  BRD4 is a Histone Acetyltransferase that Evicts Nucleosomes from Chromatin , 2016, Nature Structural &Molecular Biology.

[23]  Valerie M. Weaver,et al.  Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors , 2015, Molecular biology of the cell.

[24]  Junjie Chen,et al.  Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins. , 2015, Cell reports.

[25]  B. Győrffy,et al.  Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1 , 2015, Science Signaling.

[26]  R. Pazdur,et al.  FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer , 2015, Clinical Cancer Research.

[27]  M. Ying,et al.  Abstract 4444: Small molecule drug Verteporfin inhibits TAZ/YAP-driven signaling and tumorigenicity of breast cancer cells , 2015 .

[28]  K. Guan,et al.  Opposing roles of conventional and novel PKC isoforms in Hippo-YAP pathway regulation , 2015, Cell Research.

[29]  I. Vitale,et al.  The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications , 2015, Expert Reviews in Molecular Medicine.

[30]  Yasufumi Yamamoto,et al.  Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers , 2015, FEBS open bio.

[31]  Xiaolong Yang,et al.  Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling , 2015, Oncotarget.

[32]  J. Palacios,et al.  Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. , 2015, Endocrine-related cancer.

[33]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Bonnie L Boster,et al.  Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[35]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[36]  J. Luk,et al.  Targeting Hippo pathway by specific interruption of YAP‐TEAD interaction using cyclic YAP‐like peptides , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  A. Mercurio,et al.  A laminin 511 matrix is regulated by TAZ and functions as the ligand for the α6Bβ1 integrin to sustain breast cancer stem cells , 2015, Genes & development.

[38]  G. Semenza,et al.  Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype , 2014, Oncotarget.

[39]  Dietrich Büsselberg,et al.  Auranofin, an Anti-Rheumatic Gold Compound, Modulates Apoptosis by Elevating the Intracellular Calcium Concentration ([Ca2+]i) in MCF-7 Breast Cancer Cells , 2014, Cancers.

[40]  J. Asara,et al.  Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. , 2014, Cell reports.

[41]  Maxime Blijlevens,et al.  Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets , 2014, Oncotarget.

[42]  S. Dupont,et al.  The biology of YAP/TAZ: hippo signaling and beyond. , 2014, Physiological reviews.

[43]  R. Maria,et al.  The Hippo transducer TAZ as a biomarker of pathological complete response in HER2-positive breast cancer patients treated with trastuzumab-based neoadjuvant therapy , 2014, Oncotarget.

[44]  S. Cohen,et al.  Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover , 2014, The EMBO journal.

[45]  W. Jung,et al.  Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer. , 2014, International journal of clinical and experimental pathology.

[46]  D. Kalderon,et al.  Coupling of Hedgehog and Hippo pathways promotes stem cell maintenance by stimulating proliferation , 2014, The Journal of cell biology.

[47]  P. Khanal,et al.  YAP-induced resistance of cancer cells to antitubulin drugs is modulated by a Hippo-independent pathway. , 2014, Cancer research.

[48]  Prashant Kumar,et al.  Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer. , 2014, Cancer genomics & proteomics.

[49]  Xaralabos Varelas,et al.  The Transcriptional Regulators TAZ and YAP Direct Transforming Growth Factor β-induced Tumorigenic Phenotypes in Breast Cancer Cells*♦ , 2014, The Journal of Biological Chemistry.

[50]  M. Biffoni,et al.  TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells , 2014, Oncogene.

[51]  Lin Mei,et al.  Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility , 2013, Proceedings of the National Academy of Sciences.

[52]  S. Dedhar,et al.  Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase , 2013, Nature Communications.

[53]  G. Halder,et al.  The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment , 2013, Nature Reviews Drug Discovery.

[54]  W. Hong,et al.  Actin-binding and Cell Proliferation Activities of Angiomotin Family Members Are Regulated by Hippo Pathway-mediated Phosphorylation* , 2013, The Journal of Biological Chemistry.

[55]  P. Bult,et al.  Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer , 2013, Cellular Oncology.

[56]  Xiaolong Yang,et al.  BMP4 is a novel transcriptional target and mediator of mammary cell migration downstream of the Hippo pathway component TAZ. , 2013, Cellular signalling.

[57]  P. Maroni,et al.  Hypoxia inducible factor-1 is activated by transcriptional co-activator with PDZ-binding motif (TAZ) versus WWdomain-containing oxidoreductase (WWOX) in hypoxic microenvironment of bone metastasis from breast cancer. , 2013, European journal of cancer.

[58]  Qifeng Yang,et al.  Prognostic significance of mammalian sterile 20-like kinase 1 in breast cancer , 2013, Tumor Biology.

[59]  F. Camargo,et al.  The Ets transcription factor GABP is a component of the hippo pathway essential for growth and antioxidant defense. , 2013, Cell reports.

[60]  Robert P. Jenkins,et al.  Mechano-transduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer associated fibroblasts , 2013, Nature Cell Biology.

[61]  K. Guan,et al.  The Hippo pathway: regulators and regulations. , 2013, Genes & development.

[62]  R. Hynes,et al.  The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain , 2012, Proceedings of the National Academy of Sciences.

[63]  F. Camargo,et al.  The Hippo signaling pathway and stem cell biology. , 2012, Trends in cell biology.

[64]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[65]  Zhongmei Zhou,et al.  Tumorigenesis and Neoplastic Progression YAP Promotes Breast Cell Proliferation and Survival Partially through Stabilizing the KLF 5 Transcription Factor , 2012 .

[66]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[67]  Diego Miranda-Saavedra,et al.  TGFβ induces the formation of tumour-initiating cells in claudinlow breast cancer , 2012, Nature Communications.

[68]  S. Bicciato,et al.  The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.

[69]  N. Ibrahim,et al.  Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study , 2011, Clinical Cancer Research.

[70]  Y. She,et al.  LATS1 tumor suppressor is a novel actin-binding protein and negative regulator of actin polymerization , 2011, Cell Research.

[71]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[72]  Karen A Gelmon,et al.  Exemestane for breast-cancer prevention in postmenopausal women. , 2011, The New England journal of medicine.

[73]  Xiaolong Yang,et al.  Taxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGF. , 2011, Cancer research.

[74]  S. Lowe,et al.  AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma , 2011, Oncogene.

[75]  G. Halder,et al.  Hippo signaling: growth control and beyond , 2011, Development.

[76]  Y. Xiong,et al.  PP1 Cooperates with ASPP2 to Dephosphorylate and Activate TAZ* , 2010, The Journal of Biological Chemistry.

[77]  Ricardo H Álvarez,et al.  Present and future evolution of advanced breast cancer therapy , 2010, Breast Cancer Research.

[78]  Xiaolong Yang,et al.  LATS tumor suppressor: A new governor of cellular homeostasis , 2010, Cell cycle.

[79]  Zhengyu Zha,et al.  The Hippo Tumor Pathway Promotes TAZ Degradation by Phosphorylating a Phosphodegron and Recruiting the SCFβ-TrCP E3 Ligase* , 2010, The Journal of Biological Chemistry.

[80]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[81]  K. McMasters,et al.  Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer , 2010, Cancer.

[82]  Frederic A. Fellouse,et al.  The Hippo pathway regulates Wnt/beta-catenin signaling. , 2010, Developmental cell.

[83]  Yan Sun,et al.  Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  A. Knebel,et al.  JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis , 2010, Cell Death and Disease.

[85]  M. Khanfar,et al.  Semisynthetic Latrunculin Derivatives as Inhibitors of Metastatic Breast Cancer: Biological Evaluations, Preliminary Structure–Activity Relationship and Molecular Modeling Studies , 2010, ChemMedChem.

[86]  C. Hudson,et al.  c-Abl phosphorylation of ΔNp63α is critical for cell viability , 2010, Cell Death and Disease.

[87]  Zhengyu Zha,et al.  TEAD Transcription Factors Mediate the Function of TAZ in Cell Growth and Epithelial-Mesenchymal Transition* , 2009, Journal of Biological Chemistry.

[88]  K. Gelmon,et al.  QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model , 2009, Breast Cancer Research.

[89]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  Brian A. Hemmings,et al.  NDR Kinase Is Activated by RASSF1A/MST1 in Response to Fas Receptor Stimulation and Promotes Apoptosis , 2008, Current Biology.

[91]  Jiandie D. Lin,et al.  TEAD mediates YAP-dependent gene induction and growth control. , 2008, Genes & development.

[92]  C. Mein,et al.  Yes-associated protein (YAP) functions as a tumor suppressor in breast , 2008, Cell Death and Differentiation.

[93]  Q. Zeng,et al.  A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. , 2008, Cancer research.

[94]  W. Deng,et al.  The Hippo Pathway Promotes Notch Signaling in Regulation of Cell Differentiation, Proliferation, and Oocyte Polarity , 2008, PloS one.

[95]  Q. Zeng,et al.  The emerging role of the hippo pathway in cell contact inhibition, organ size control, and cancer development in mammals. , 2008, Cancer cell.

[96]  M. Khanfar,et al.  Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. , 2008, Journal of natural products.

[97]  R. Jaenisch,et al.  YAP1 Increases Organ Size and Expands Undifferentiated Progenitor Cells , 2007, Current Biology.

[98]  Erica A Golemis,et al.  Selective Raf inhibition in cancer therapy , 2007, Expert opinion on therapeutic targets.

[99]  Walter Kolch,et al.  RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. , 2007, Molecular cell.

[100]  Y. Shaul,et al.  The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73 , 2007, Cell Death and Differentiation.

[101]  V. Gandin,et al.  Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. , 2007, Free radical biology & medicine.

[102]  Y. Miyoshi,et al.  Low LATS2 mRNA level can predict favorable response to epirubicin plus cyclophosphamide, but not to docetaxel, in breast cancers , 2007, Journal of Cancer Research and Clinical Oncology.

[103]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[104]  Jianmin Zhang,et al.  Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon , 2006, Proceedings of the National Academy of Sciences.

[105]  Judit Villén,et al.  A Conserved MST-FOXO Signaling Pathway Mediates Oxidative-Stress Responses and Extends Life Span , 2006, Cell.

[106]  M. Berger,et al.  Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. , 2006, Cancer research.

[107]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[108]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[109]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[110]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[111]  Vikas Khurana,et al.  Statins to reduce breast cancer risk: A case control study in U.S. female veterans , 2005 .

[112]  G. Blandino,et al.  The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. , 2005, Molecular cell.

[113]  P. Opolon,et al.  Anti-RhoA and anti-RhoC siRNAs inhibit the proliferation and invasiveness of MDA-MB-231 breast cancer cells in vitro and in vivo. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[114]  Walter Kolch,et al.  Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1 , 2004, Science.

[115]  Xiaolong Yang,et al.  LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1 , 2004, Nature Cell Biology.

[116]  R. Schiff,et al.  Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. , 2004, Journal of the National Cancer Institute.

[117]  N. Navin,et al.  WW Domain-containing Protein YAP Associates with ErbB-4 and Acts as a Co-transcriptional Activator for the Carboxyl-terminal Fragment of ErbB-4 That Translocates to the Nucleus* , 2003, Journal of Biological Chemistry.

[118]  Jonathan Chernoff,et al.  Apoptotic Phosphorylation of Histone H2B Is Mediated by Mammalian Sterile Twenty Kinase , 2003, Cell.

[119]  R. Sékaly,et al.  HIV-1 protease processes procaspase 8 to cause mitochondrial release of cytochrome c, caspase cleavage and nuclear fragmentation , 2002, Cell Death and Differentiation.

[120]  A. Howell,et al.  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[121]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  T. Xu,et al.  Human homologue of Drosophila lats, LATS1, negatively regulate growth by inducing G2/M arrest or apoptosis , 2001, Oncogene.

[123]  L. Castagnoli,et al.  Physical Interaction with Yes-associated Protein Enhances p73 Transcriptional Activity* , 2001, The Journal of Biological Chemistry.

[124]  C. Haipek,et al.  The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. , 2001, Genes & development.

[125]  Katsuyoshi Hatakeyama,et al.  Zyxin, a Regulator of Actin Filament Assembly, Targets the Mitotic Apparatus by Interacting with H-Warts/Lats1 Tumor Suppressor , 2000, The Journal of cell biology.

[126]  W. Tao,et al.  Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction , 1999, Nature Genetics.

[127]  M. Dukes,et al.  The preclinical pharmacology of “Arimidex” (Anastrozole; ZD1033) — a potent, selective aromatase inhibitor , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[128]  Doriano Fabbro,et al.  Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase , 1996, Nature Medicine.

[129]  Xiaolong Yang,et al.  Targeting the Hippo Pathway to Improve Response to Chemotherapy , 2019, Targeting Cell Survival Pathways to Enhance Response to Chemotherapy.

[130]  T. K. Eisinger-Mathason,et al.  Targeting the Hippo pathway: Clinical implications and therapeutics. , 2016, Pharmacological research.

[131]  Ceshi Chen,et al.  Hippo pathway in mammary gland development and breast cancer. , 2015, Acta biochimica et biophysica Sinica.

[132]  G. Giamas,et al.  LATS2 is a modulator of estrogen receptor alpha. , 2013, Anticancer research.

[133]  Zhongmei Zhou,et al.  TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. , 2012, Carcinogenesis.

[134]  K. Gelmon,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[135]  F. Cardoso,et al.  Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[136]  K. Guan,et al.  A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). , 2010, Genes & development.

[137]  G. Melino,et al.  Yes-Associated Protein (YAP) is a critical mediator of c-Jun-dependent apoptosis , 2008, Cell Death and Differentiation.

[138]  J. Downward,et al.  Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. , 2003, Molecular cell.

[139]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.